TB Alliance, Takeda Advance TB Therapy Program
News Jun 23, 2016
The joint research program is funded through the Global Health Innovative Technology (GHIT) Fund, established for the purpose of promoting research and development of pharmaceutical products, vaccines and diagnostics needed for communicable diseases.
In June 2013, TB Alliance and Takeda initiated a program to screen Takeda’s library of 20,000 proprietary compounds to identify potential candidates that showed promise to be further developed into new TB treatments. This new collaboration advances the successful hits from the screening program, which was also funded by GHIT Fund. This partnership complements TB Alliance’s existing work in advancing the pipeline for new TB drugs. For Takeda, this program with TB Alliance is an excellent opportunity to leverage, as part of Takeda’s corporate social responsibility program, the company’s drug discovery expertise for communicable diseases, in addition to Takeda’s focus on the oncology, gastroenterology and central nervous system therapeutic areas.
TB is the leading infectious disease killer in the world. According to the World Health Organization (WHO), 9.6 million people were infected with TB in 2014. In the same year, 1.5 million people lost their lives to the disease, 95% of whom lived in low- to middle-income countries.
Today’s existing TB treatments are complicated and require a minimum of six months of treatment, imposing a heavy burden on patients, families, and healthcare systems. Treatment for drug-resistant tuberculosis can take two years or longer and is much more expensive and complicated. Given this global health threat, new TB drugs and regimens that are simpler to administer, are of shorter duration, and can overcome drug resistance are urgently needed.
The collaboration will leverage both TB Alliance’s and Takeda’s experience, knowledge and technology to discover and pursue optimal lead compounds for intervention against TB. Through these initiatives, TB Alliance and Takeda aim to contribute to the eradication of TB and improve the health and quality of life for millions of people.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE